Azerion publishes interim Q2 and H1 2023 results
August 31, 2023 01:00 ET
|
Azerion Group NV
Platform growth and integrations leading to increased revenue and improved margins Highlights of Q2 2023 Increased earnings driven by revenue growth and ongoing cost savingsNet revenue of...
Aclarion, Inc. Announces Filing of Delayed 10-Q Quarterly Report
August 25, 2023 16:10 ET
|
Aclarion, Inc.
BROOMFIELD, CO, Aug. 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging...
NAPCO: Kaplan Fox Investigates Potential Securities Fraud at Napco Security Technologies, Inc.
August 22, 2023 15:04 ET
|
Kaplan Fox & Kilsheimer LLP
NEW YORK, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of NAPCO Security Technologies, Inc. (“NAPCO” or the...
Immatics veröffentlicht Ergebnisse des zweiten Quartals 2023 sowie ein Update zur Geschäftsentwicklung
August 17, 2023 07:00 ET
|
Immatics N.V.
Klinische Phase-1/2-Studie zur Untersuchung von Immatics‘ zweitem bispezifischen TCR-Programm der nächsten Generation mit verlängerter Halbwertszeit, TCER® IMA402 (Zielstruktur: PRAME),...
Immatics Announces Second Quarter 2023 Financial Results and Business Update
August 17, 2023 07:00 ET
|
https://immatics.com/
Phase 1/2 clinical trial initiated evaluating Immatics’ second next-generation half-life extended TCR Bispecific program, TCER® IMA402 targeting PRAMEACTengine® IMA203 TCR-T monotherapy against PRAME...
INTERIM FINANCIAL REPORT Q1 2023 - Jøtul AS
May 31, 2023 02:15 ET
|
Jøtul AS
The Jøtul Group (representing Jøtul AS together with its subsidiaries) is one of the three largest suppliers of fireplaces in Europe and a significant player in North America. The company, with a...
Immatics veröffentlicht Ergebnisse des ersten Quartals 2023 sowie ein Update zur Geschäftsentwicklung
May 16, 2023 07:00 ET
|
Immatics N.V.
Klinisches Daten-Update von 11 stark vorbehandelten Patienten aus Phase 1b Dosisexpansionskohorte A mit ACTengine® IMA203 TCR-T Monotherapie gegen Zielstruktur PRAME zeigte eine bestätigte objektive...
Immatics Announces First Quarter 2023 Financial Results and Business Update
May 16, 2023 07:00 ET
|
https://immatics.com/
ACTengine® IMA203 TCR-T monotherapy against PRAME showed 67% confirmed ORR in an interim clinical update on heavily pre-treated 11 patients in Phase 1b dose expansion Cohort A with median duration of...
Connexa Sports Technologies Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
March 24, 2023 08:30 ET
|
Connexa Sports Technologies Inc.
Baltimore, March 24, 2023 (GLOBE NEWSWIRE) -- Connexa Sports Technologies Inc. (NASDAQ: CNXA) (www.connexasports.com) (the “Company”) announced that it received a letter from The Nasdaq Stock Market...
Immatics veröffentlicht Ergebnisse des Geschäftsjahres 2022 sowie ein Update zur Geschäftsentwicklung
March 21, 2023 07:31 ET
|
Immatics N.V.
ACTengine® IMA203 TCR-T-Monotherapie gegen die Zielstruktur PRAME zeigte in einer Zwischenanalyse der klinischen Daten im Oktober 2022 eine bestätigte objektive Ansprechrate (confirmed objective...